Cellesce was founded in 2013 and is built on biochemical and bioprocess engineering expertise from the University of Bath and cell and organoid biology expertise from Cardiff University. In December 2017 Cellesce moved into the Medicentre in Cardiff, Wales.
Cellesce has invented and patented a unique bioprocess for the expansion of human-derived, cancer organoids for applications in cancer drug discovery. Organoids are three-dimensional, multi-cellular clusters, derived from patient cancer biopsy tissue. They are propagated and amplified in the laboratory and fully recapitulate all of the different cell types and underlying pathology of the original tissues. They are, in effect, mini-tumours. Previously, organoids could only be grown and expanded manually. This is a technically challenging, time-consuming and labour-intensive process resulting in small numbers of inconsistently-sized organoids, limiting their suitability for use in high throughput screening and widespread commercial use.